Clinical trial
A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa)…
NCT00267007 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Terminated
Key facts
| NCT number | NCT00267007 |
|---|---|
| Title | A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) on the Development of Peripheral Neuropathy in Patients Receiving Combination Taxane and Platinum-Based Chemotherapy for Cancer |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho Biotech Clinical Affairs, L.L.C. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral Neuropathy, Chemotherapy-induced |
| Intervention type | Drug |
| Interventions | PROCRIT 40, 000 IU QW, Placebo |
| Enrollment | 32 |
| Start date | Jun 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Dec 20, 2005 |
| Last update posted | Jun 4, 2014 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: